Allergy Therapeutics Sees End FDA Hold if Cervarix Approved – Wall Street Journal


 Allergy Therapeutics Sees End FDA Hold If Cervarix Approved   Wall Street Journal
Allergy Therapeutics Sees End FDA Hold If Cervarix Approved
Wall Street Journal
An approval would mark a positive change in the environment for Allergy's US plans for its Pollinex Quattro hayfever vaccine, Allergy said. Like Cervarix, it uses the vaccine adjuvant MPL to boost its effectiveness, but the FDA halted a major trial of


Comments are closed.